First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter-Reference-Cited by-同舟云学术

First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter

Published:2022-11-02 Issue:11 Volume:21 Page:1742-1743
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:

Author:

de Rauglaudre Bernadette¹²³^ORCID,Finetti Pascal¹³^ORCID,Birnbaum David Jérémie¹³⁴^ORCID,Lopez Marc¹³^ORCID,Bertucci François¹³⁵^ORCID,Mamessier Emilie¹³^ORCID

Affiliation:

1. 1Laboratory of Predictive Oncology, Centre de Recherche en Cancerologie de Marseille, Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, “Equipe labellisee Ligue Contre le Cancer”, Marseille, France.

2. 2Departement d'Oncologie Digestive, Hopital de la Timone, Assistance Publique – Hopitaux de Marseille (APHM), Marseille, France.

3. 3Aix-Marseille University, France.

4. 4Departement de Chirurgie digestive, Hopital Nord, APHM, Marseille, France.

5. 5Departement d'Oncologie Medicale, Institut Paoli-Calmettes, Marseille, France.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/mct/article-pdf/21/11/1742/3218868/1742.pdf

Reference5 articles.

1. A first-in-human, phase 1, multicenter, open-label, dose-escalation study of PCA062, an antibody-drug conjugate targeting P-cadherin, in patients with solid tumors;Duca;Mol Cancer Ther,2022

2. PCA062, a P-cadherin targeting antibody-drug conjugate, displays potent antitumor activity against P-cadherin-expressing Malignancies;Sheng;Mol Cancer Ther,2021

3. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1;Ogitani;Clin Cancer Res,2016

4. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial;Siena;Lancet Oncol,2021

5. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer;Shitara;N Engl J Med,2020